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Several studies have evidenced variations in plasma glycosaminoglycans content in physiological and pathological conditions. In
normal human plasma GAGs are present mainly as undersulfated chondroitin sulfate (CS). The aim of the present study was
to evaluate possible correlations between plasma CS level/structure and the presence/typology of carotid atherosclerotic lesion.
Plasma CS was puriﬁed from 46 control subjects and 47 patients undergoing carotid endarterectomy showing either a soft or a
hardplaque.TheconcentrationandstructuralcharacteristicsofplasmaCSwereassessedbycapillaryelectrophoresisofconstituent
unsaturated ﬂuorophore-labeled disaccharides. Results showed that the concentration of total CS isomers was increased by 21.4%
(P<0.01) in plasma of patients, due to a signiﬁcant increase of undersulfated CS. Consequently, in patients the plasma CS charge
density was signiﬁcantly reduced with respect to that of controls. After sorting for plaque typology, we found that patients with
soft plaques and those with hard ones diﬀerently contribute to the observed changes. In plasma from patients with soft plaques,
the increase in CS content was not associated with modiﬁcations of its sulfation pattern. On the contrary, the presence of hard
plaques was associated with CS sulfation pattern modiﬁcations in presence of quite normal total CS isomers levels. These results
suggest that the plasma CS content and structure could be related to the presence and the typology of atherosclerotic plaque and
could provide a useful diagnostic tool, as well as information on the molecular mechanisms responsible for plaque instability.
1.Introduction
Atherosclerosis is a progressive disease characterized by the
accumulation of lipids and ﬁbrous elements in medium
and large arteries. Plaque rupture and thrombosis are the
most important clinical complication in the pathogenesis of
acute coronary syndromes and peripheral vascular disease
[1, 2]. Although numerous risk factors such as hypertension,
diabetes, and hyperlipidemia are thought to play a role in
the development and progression of this pathology [3], the
mechanisms underlying plaque formation and progression
are still largely unknown. Abnormal expression and struc-
tural modiﬁcations of arterial chondroitin sulfate proteo-
glycans (CS-PGs) have been implicated in atherosclerosis
progression [4–6]. Arterial CS-PGs are markedly increased
in early atherosclerotic lesions, participating in lipid reten-
tion, modiﬁcation, and accumulation. Furthermore, CS-
PGs play a key role in inﬂammation processes associated
with atherosclerosis [6]. Numerous in situ lines of evidence
indicate that plaque instability is caused by a substantial
increase of both proteolytic activity and inﬂammatory state
[7]. However, nowadays speciﬁc systemic markers for early
diagnosisandprognosisofatheromatouslesionshavenotyet
been identiﬁed.
Several studies have evidenced variations in plasma gly-
cosaminoglycan (GAG) levels associated with both physio-
logical and pathological conditions, such as strong physical2 Biochemistry Research International
training [8], chronic lymphocytic leukaemia and essen-
tial thrombocythaemia [9], lupus erythematosus [10], and
mucopolysaccharidosis [11, 12].
Chondroitin sulfate (CS) is the main GAG in normal
human plasma. It consists of 12–18 repeating disaccharide
units, each containing a hexuronic acid linked by β (1→3)
bond to a N-acetyl-D-galactosamine residue, of which about
30% is sulfated at C-4 hydroxyl group of the hexosamine. It
circulates covalently linked to the proteoglycan bikunin [13],
a light subunit carrying the antiproteinase activity of plasma
serine-proteinaseinter-α-inhibitor(IαI).Severaldatasuggest
that bikunin plays an important role in inﬂammation.
The IαI family molecules are synthesized in hepatocytes
where one or two polypeptides, called the heavy chains
(HCs), are linked to the CS chain of bikunin. After a
stimulus, the IαI molecules leave the circulation and, in
extravascular sites, the HCs are transferred from CS chain
to the locally synthesized hyaluronic acid (HA) to form the
serum-derived hyaluronan-associated-protein- (SHAP-) HA
complex, which plays important roles in stabilizing extracel-
lular matrices and it is often associated with inﬂammatory
conditions[14].Moreover,ithasbeendescribedthatbikunin
also acts as a growth factor for endothelial cells, regulates
the intracellular calcium levels, and inhibits kidney stone
formation and smooth muscle cell contraction [15].
The aim of the present study was to evaluate possible
correlations between plasma chondroitin sulfate (CS) level/
structure and the presence/typology of carotid atheroscle-
rotic lesion.
2.MaterialsandMethods
2.1. Sample Collection. CS isomers analyses were conducted
on preoperative plasma samples from 47 patients (stenosis >
70%, 70.4 ± 7.9 years old) undergoing carotid endarterec-
tomy, showing either a soft (26 patients) or a hard (21
patients) plaque, and from 46 healthy normolipidemic
volunteers (control group), aged from 20 to 75 (47.8 ±
14.4 years old). The main clinical parameters of the patients
under study are reported in Table 1. Lipid proﬁles and
homocysteine levels in patients and controls are reported in
Table 2. Plaque typology was assessed by ultrasonography
using a Mylab 70 Xvision ecocolordoppler equipped with
a LA332 AppleProbe 11–3MHz (Esaote). Plaques were
classiﬁed according to the Gray-Weale classiﬁcation [16]i n
soft,withhypoechoicfeatures(types1and2),andhard,with
h y p e r e c h o i cf e a t u r e s( t y p e s3 ,4 ,a n d5 ) .I n f o r m e dc o n s e n t
was obtained before enrolment. The study was approved by
the local ethical committees in accordance with institution
guidelines.
2.2. Plasma CS Isomers Analysis. GAG puriﬁcation was per-
formed by a microanalytic preparative method, as previously
described [17]. Brieﬂy, 500μL of plasma samples were
subjected to proteolytic treatment with papain. Plasma
CS was puriﬁed by anion exchange chromatography and
precipitated with 5 volumes of ethanol at −20◦Cf o r2 4 h .
Subsequently, puriﬁed plasma CS isomers were subjected to
depolymerization by using chondroitin ABC lyase (0.1U per
Table 1: Main clinical parameters of the 47 patients undergoing
carotid endarterectomy according to plaque typology.
Hard (21) Soft (26) All (47)
Age 70.9 ± 5.1 70.2 ± 9.3 70.4 ± 7.9
Sex ratio (m/f) 2/1 1.3/1 1.6/1
Body mass index (kg/m2) 26.9 ± 3.4 27.9 ± 3.8 27.5 ± 3.6
Symptomatic (%) 44.4 56.2 51
Transient ischemic attack (%) 33.3 25 28
Ictus (%) 11.1 31.2 22
Diabetes (%) 44.4 25 34
On therapy (%) 75 75 75
HbA1C (%) 4.5 ± 2.6 4.5 ± 3.0 4.5 ± 2.8
Hypertension (%) 100 93.75 97
On therapy (%) 100 100 100
Dyslipidemic (%) 77.8 75 76
On therapy (%) 100 100 100
Smokers (%) 77.8 68.7 73.0
CRP (mg/dL) 1.16 ± 1.05 1.34 ± 0.84 1.26 ± 0.92
100μg hexuronic acid) and the unsaturated disaccharides
were derivatized with 0.1mol/L 2-aminoacridone (AMAC)
[18].
Separation and quantitation of chondroitin sulfate-
derived disaccharides was obtained by capillary elec-
trophoresis (CE) analysis by using a P/ACE capillary elec-
trophoresis system (Beckman) equipped with a 75mm id
and 47cm length uncoated fused-silica capillary using a
60mmol/L sodium acetate buﬀer, containing 0.05% methyl-
cellulose [17]. Separations were carried out at 25◦Ca n d
monitored with a laser-induced ﬂuorescence (LIF) detector
at 488nm excitation and 520nm emission wavelengths. For
quantitative analyses a homemade standard CS was puriﬁed
fromhumanplasmapoolsbyapreparativeapproach.Brieﬂy,
standard CS isomers were obtained from papain-treated
plasma by anion exchange chromatography, assayed for
hexuronic acid content [19], lyophilized into aliquots, and
stored at −20◦C. For Δ-disaccharide analyses, a calibration
curve was determined by submitting plasma-puriﬁed CS iso-
mers to chondroitin ABC lyase treatment and derivatization
procedure.
CS levels were expressed as μg of hexuronic acid per mL
of plasma (μgUA/mL), and CS charge density was evaluated
as ratio of 4-sulfated Δ-disaccharides (ΔDi-4S) and total
unsaturated disaccharides (ΔDi-4S + ΔDi-nonS).
2.3. Statistical Analyses. Statistical analyses were conducted
by using SigmaStat software (Systat Software, Inc.). Student’s
t-test was used for evaluating diﬀerences between normally
distributed data, while the Mann-Whitney Rank Sum test
was applied to nonparametric ones. Values of P<0.05
were considered to be signiﬁcant. Correlations between CS
content, CS charge density, and age were determined by
the Pearson Product Moment Correlation test with 95%
conﬁdence intervals.Biochemistry Research International 3
Table 2: Lipid proﬁles and homocysteine levels in patients and controls.
Hard (21) Soft (26) All patients (47) Controls (46)
Age 70.9 ± 5.1 70.2 ± 9.3 70.4 ± 7.9 47.8 ± 14.4
Sex ratio (m/f) 2/1 1.3/1 1.6/1 1/1.5
Triglycerides (mg/dL) 119.9 ± 55.1 112.7 ± 67.1 115.4 ± 61.7 86.6 ± 28.7
Total cholesterol (mg/dL) 187.9 ± 43.3 164.5 ± 38.3 173.2 ± 41.0 175.7 ± 17.5
LDL cholesterol (mg/dL) 102.4 ± 35.9 90.9 ± 35.6 95.2 ± 35.4 108.3 ± 12.6
HDL cholesterol (mg/dL) 61.2 ± 17.0 51.5 ± 10.9 55.1 ± 14.0 50.1 ± 10.9
Homocysteine (μmol/L) 12.5 ± 4.7 11.5 ± 4.1 11.8 ± 4.3 10.32 ± 3.27
Table 3: Total plasma CS, ΔDi-4S, and ΔDi-nonS levels and CS charge density in control subjects, in the totality of patients and according
to plaque typology.
Total CS (μgUA/mL) ΔDi-4S (μgUA/mL) ΔDi-nonS (μgUA/mL) #CS charge density (%)
Controls (n = 46) 5.17 ± 1.48 1.61 ± 0.56 3.56 ± 0.99 30.8 ± 4.5
Patients (n = 47) 6.28 ± 2.28 1.82 ± 0.77 4.46 ± 1.59 28.6 ± 4.6
Soft (n = 26) 6.76 ± 2.16 2.03 ± 0.75 4.73 ± 1.48 29.7 ± 4.0
Hard (n = 21) 5.69 ± 2.34 1.57 ± 0.74 4.12 ± 1.69 27.1 ± 4.8
Patient versus control 0.009∗ 0.132 0.002 0.022
Soft versus control <0.001 0.017 0.001 0.337
Hard versus control 0.321∗ 0.81 0.169 0.004
Hard versus soft 0.114 0.04 0.202 0.055
P values obtained by Student’s t-tests for normally distributed parameters or by ∗the Mann-Whitney Rank Sum tests for nonparametric ones are reported.
#CS charge density was evaluated as ratio between ΔDi-4S and the sum of ΔDi-nonS and ΔDi-4S. Signiﬁcant diﬀerences are reported in bold (P<0.05).
3. Results
Plasma samples from atherosclerotic patients and from
healthy volunteers were analysed. Patients were sorted in
two groups according to the typology of their carotid
lesion (either soft or hard) as evaluated by ecocolordoppler
ultrasonography. The two groups of patients did not diﬀer
for the main clinical (Table 1) and biochemical parameters
(Table 2), neither as a whole nor subsorting for gender. Lipid
proﬁles and homocysteine levels (Table 2) were similar in
patient and control groups (P>0.05).
CE was used to analyze the quantity and ﬁne structure
of plasma CS isomers. The adopted method allows the
simultaneous determination of hyaluronan- and CS-derived
disaccharides with a good reproducibility of both the
migration times (CV%, 0.25) and the peak areas (CV%,
1.4). Intra- and interassay CVs were 5.37 and 7.23%,
respectively, and analytical recovery was about 86% [17].
This method has been validated by a comparison with
a reference assay (ﬂuorophore-assisted carbohydrate gel
electrophoresis) using the Passing and Bablock regression
analysis and the Bland-Altman test as speciﬁc statistical
methods for measurement comparison [17].
CEanalysesofplasmaCSisomersshowedthepresenceof
two main unsaturated disaccharides, the nonsulfated (ΔDi-
nonS) and the 4-monosulfated (ΔDi-4S).
To rule out any inﬂuence of age on our analytical and
structural results, we evaluated its association with both
content and charge density of plasma CS in control group.
In this respect, no correlation was found even after sorting
controls for gender. The age did not correlate neither with
ΔDi-nonS (r =− 0.219; P = 0.143) nor with ΔDi-4S (r =
−0.002; P = 0.143) levels.
Statistical analyses allowed us to evidence signiﬁcant
diﬀerences between the whole group of patients and the
g r o u po fc o n t r o l s( T a b l e3) consisting in an increase
of undersulfated CS levels (4.46 ± 1.59 versus 3.56 ±
0.99μgUA/mL, P = 0.002), with consequent increase of
total CS content (6.28 ± 2.28 versus 5.17 ± 1.48μgUA/mL,
P = 0.009) and reduction in its charge density (28.6 ± 4.6
versus 30.8 ± 4.5%, P = 0.022). Interestingly, after sorting
for plaque typology, we evidenced signiﬁcant diﬀerences in
total CS concentration only in patients with a soft plaque
with respect to healthy subjects (6.76 ± 2.16 versus 5.17 ±
1.48μgUA/mL, P<0.001), due to signiﬁcantly higher levels
of both ΔDi-nonS (4.73 ± 1.48 versus 3.56 ± 0.99μgUA/mL,
P = 0.001) and ΔDi-4S (2.03 ± 0.75 versus 1.61 ± 0.56,
P = 0.017), whereas patients with hard plaques showed quite
normal levels. In plasma from patients with a soft plaque
both normosulfated and undersulfated CS isomers were
signiﬁcantly increased and their relative proportions were
unchanged. So, no signiﬁcant changes in CS charge density
were detected. On the contrary, in plasma from patients
with hard plaques, although the levels of both CS isomers
were quite normal, a signiﬁcant diﬀerence in their relative
proportions was found with respect to controls, producing a
signiﬁcantly lower CS charge density (−12%).
No diﬀerencesbyStudent’st-testinbothtotalCScontent
andCSchargedensityemergedaftersubsortingbothpatients
and controls for gender.4 Biochemistry Research International
4. Discussion
Humannormalplasmacontainsprincipallyanundersulfated
form of chondroitin at a concentration of about 4μgUA/mL
[20], whose origin and physiological roles have not yet been
fullyelucidated.Itcirculatescovalentlylinkedtobikunin[13,
14], or as a main product of tissue catabolism or produced
by blood cells, such as lymphocytes, associated with a variety
of plasma proteins [21, 22]. It is known that the plasma
GAG association with low-density lipoproteins could aﬀect
some of their physicochemical properties [23] and that some
physiological and pathological conditions could lead to an
increase in plasma GAG levels [8–12]. Moreover, mediators
of inﬂammation such as some cytokines and growth factors
are able to modulate the size, the degree, and the pattern of
sulfation, as well as the degree of epimerization of the GAG
chains [24–26].
In this work we studied possible correlations between
plasma CS level/structure and presence/typology of carotid
atheroscleroticlesion.Inapreviouspaper[17],wedeveloped
a sensitive and reproducible analytical method for the
quantitative and structural evaluation of human plasma CS
isomers using capillary electrophoresis (CE). Herein, this
analytical approach was adopted to evaluate CS concen-
trations and structural characteristics in 46 healthy human
subjectsandin47atheroscleroticpatientshavingeitherasoft
or a hard plaque.
Plaque typology was assessed by duplex ultrasonography
which represents a noninvasive method for the carotid
plaquecharacterization.Thistechniqueallowstodetectareas
with diﬀerent shades of grey that provide information on
plaque consistency. In particular, hypoechoic features are
associated with lipid-rich carotid plaques, while hyperechoic
features are with ﬁbrous or ﬁbrocalciﬁc ones [16]. In
this respect, several recent ultrasound studies have demon-
strated that hypoechoic plaques, with a low GSM (gray-
scale median) value, were associated with an increased risk
of cerebrovascular ischemic events [27–29]. So, the soft
plaque shows characteristics of instability and propension
to rupture. It is generally held that plaque instability is
caused by a substantial increase in proteolytic activity and
inﬂammatory status.
To rule out any inﬂuence of age on our results, we eval-
uated its association with plasma CS content and sulfation
pattern by means of Pearson’s correlation. In this respect,
no correlation was found. Few conﬂicting data regarding
the relationship between plasma GAG content and ageing
are present in the literature. Some investigations found that
total plasma GAG content does not vary with age [30, 31].
Conversely, a positive correlation between total plasma GAG
levels and age has been reported in males [32]. Qualitative
analysis of intact plasma GAGs by using cellulose acetate
electrophoresis has shown a decline of CS with proceeding
age [33], while the structural analysis of plasma CS after
depolymerization with speciﬁc chondro-/dermatolyases has
revealed a signiﬁcant increase of CS amount and its charge
density depending on age [34]. On the basis of our results,
both plasma CS levels and its charge density seem to be
unaﬀected by age. Moreover, no correlation was found with
gender.
With regard to the inﬂuence of atherosclerotic lesion
presence, we found signiﬁcant diﬀerences in total plasma CS
content (+21.4%), between the group of patients and the
controls. These diﬀerences were ascribable to signiﬁcantly
higher levels of undersulfated CS in these patients (+25.3%).
The statistical analyses of the inﬂuence of atherosclerotic
lesion typology on plasma CS content and sulfation pattern
showed that in presence of soft plaques CS content was
signiﬁcantly increased, without signiﬁcant changes in its
chargedensity,whereasinpresenceofhardplaquesitscharge
density was reduced, without changes in its content.
The signiﬁcance of the observed modiﬁcations in plasma
CS isomers of patients undergoing endarterectomy could be
related to diﬀerent PG/GAG metabolism in vascular tissue in
presence of soft/hard atherosclerotic plaques. Atherosclerosis
has been associated with a biosynthetic imbalance of chon-
droitin sulfate proteoglycans [4–6]. It has been described
that the ratio of 6-sulfated to 4-sulfated disaccharides is
increased in atherosclerotic type II aortas and signiﬁcantly
decreased in atherosclerotic type V, indicating that vascular
concentration of GAGs is diﬀerently aﬀected during the
progression of the disease [4]. Increased levels of both
undersulfated and normosulfated CS have been described
in postoperative serum samples of patients submitted to
coronary artery bypass surgery and proposed as indicative of
an inﬂammatory state of the patient [35].
In this regard, it has been reported that in inﬂammatory
diseases the CS chains carried by bikunin increase in size
proportionally to the severity of the inﬂammatory response
[36], while their sulfation degree decreases [37].
Moreover, several studies reported that sulfation pattern
ofCSisomersmaybeimportantfortheirprotectiverolefrom
oxidative damage [38–43]. The antioxidant properties of
GAGs could be explained by both GAGs chelating properties
on divalent cations (such as Cu2+ and Fe2+, responsible
for the initiation of hydroxyl radical reactions) and their
improving eﬀects on endogenous antioxidant defences. In
particular, the anti-oxidant properties of CS isomers seem
to be related to the sulfation at position 4 of galactosamine
residue of disaccharide units.
On a whole, our data show that plasma CS level and
structurearesigniﬁcantlydiﬀerentinatheroscleroticpatients
with respect to controls and that these diﬀerences do not
depend on age. Moreover, the obtained results suggest that
both content and distribution of the circulating CS isomers
are associated with the presence as well as with the typology
of carotid plaque. If plasma CS levels and structure reﬂect,
almost partly, the CS-PGs metabolism in aﬀected vascular
tissues, the determination of plasma CS isomers may provide
information on molecular mechanisms of atherosclerosis
progression.
Therefore, evaluating content and distribution of plasma
CSisomerscouldbeusefulindiagnosisofcarotidatheroscle-
rosis. Further studies on subjects with preclinical atheroscle-
rosis would be advisable. Indeed, ﬁnding an association
between these molecules and early atherosclerosis stagesBiochemistry Research International 5
couldprovideanimportanttoolforthefollow-upofpatients
inattemptingtopreventinauspiciouscerebrovascularevents.
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